Mail

UK markets close in 6 hours 20 minutes

FTSE 100
8,106.01
+27.15(+0.34%)
FTSE 250
19,811.40
+209.42(+1.07%)
AIM
755.85
+2.73(+0.36%)
GBP/EUR
1.1658
+0.0002(+0.02%)
GBP/USD
1.2522
+0.0011(+0.09%)
Bitcoin GBP
51,449.21
+275.97(+0.54%)

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Oncology Pharma Inc. (ONPH)

Other OTC - Other OTC Delayed price. Currency in USD

Add to watchlist

0.0000

+0.0000

(+900.00%)

At close: 12:05PM EDT

Currency in USD

Valuation measures⁴

Market cap (intra-day)	379.00
Enterprise value	379.00
Trailing P/E	N/A
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	0.32
Price/book (mrq)	N/A
Enterprise value/revenue	0.00
Enterprise value/EBITDA	-0.00

Trading information

Stock price history

Beta (5Y monthly)	10.78
52-week change ³	-99.99%
S&P500 52-week change ³	21.08%
52-week high ³	1.0500
52-week low ³	0.0000
50-day moving average ³	0.0002
200-day moving average ³	0.0412

Share statistics

Avg vol (3-month) ³	1.91k
Avg vol (10-day) ³	621
Shares outstanding ⁵	37.96M
Implied shares outstanding ⁶	38M
Float ⁸	N/A
% held by insiders ¹	0.00%
% held by institutions ¹	0.00%
Shares short (11 Jun 2002) ⁴	N/A
Short ratio (11 Jun 2002) ⁴	N/A
Short % of float (11 Jun 2002) ⁴	N/A
Short % of shares outstanding (11 Jun 2002) ⁴	0.02%
Shares short (prior month 10 Apr 2002) ⁴	N/A

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	09 Oct 2020
Ex-dividend date ⁴	N/A
Last split factor ²	1:100
Last split date ³	09 Oct 2020

Financial highlights

Fiscal year

Fiscal year ends	31 Mar 2013
Most-recent quarter (mrq)	31 Dec 2011

Profitability

Profit margin	1,821.37%
Operating margin (ttm)	-74.97%

Management effectiveness

Return on assets (ttm)	N/A
Return on equity (ttm)	N/A

Income statement

Revenue (ttm)	10.21k
Revenue per share (ttm)	N/A
Quarterly revenue growth (yoy)	N/A
Gross profit (ttm)	N/A
EBITDA	-8.65k
Net income avi to common (ttm)	-15.27k
Diluted EPS (ttm)	-0.0000
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	3.21k
Total cash per share (mrq)	N/A
Total debt (mrq)	788.53k
Total debt/equity (mrq)	N/A
Current ratio (mrq)	0.88
Book value per share (mrq)	N/A

Cash flow statement

Operating cash flow (ttm)	7.06k
Levered free cash flow (ttm)	N/A